13 January 2015
IntegraGen’s revenue increases 12% in 2014
IntegraGen announced today the company’s sales results for the year ending December 14, 2014 increased 12% in 2014 to € 6.04 million.
16 December 2014
Collaboration with PICCOLO study investigators for miR-31-3p
IntegraGen has announced a collaboration with the team of investigators from the PICCOLO study to further validate the role of biomarker hsa-miR-31-3p in metastatic colorectal cancer (mCRC).
15 December 2014
IntegraGen licenses liver cancer molecular signatures
IntegraGen has announced that it has entered into an agreement providing the company with the worldwide licensing rights for two hepatocellular carcinoma molecular signatures which have potential clinical utility for monitoring patients with liver cancer.
